Produtos Naturais Inibidores da Transcriptase Reversa do Vírus HIV

Gonçalves, R. S. B; Barreto, M. B; Gomes, C. R. B; Souza, M. V. N.
Rev. Fitos ; 4(1): 87-107, 2009.mar. ilus; tab
Artículo en Portugués | ACERVOFAR, FIOCRUZ | ID: far-2099

Documentos relacionados

  1. Pharmacokinetics of once-daily doravirine over 72 h following drug cessation.
  2. Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine.
  3. Leukocyte Telomere Length in HIV Infection: A Marker of Persistent Immune Aging or Transient Immune Reconstitution?
  4. Synthesis of carbon-14 and stable isotope labeled Censavudine.
  5. An <i>in silico</i> molecular modeling approach of halolactone derivatives as potential inhibitors for human immunodeficiency virus type-1 reverse transcriptase enzyme.
  6. Revolutionizing antiretroviral therapy for human immunodeficiency virus/AIDS: A computational approach using molecular docking, virtual screening, and 3D pharmacophore building to address therapeutic failure and propose highly effective candidates.
  7. Tri-substituted 1,3,5-triazine-based analogs as effective HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs): A systematic review.
  8. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
  9. Does Tenofovir-containing First-line Antiretroviral Therapy Mitigate the Impact of Pretreatment Non-nucleoside Reverse Transcriptase Inhibitor Drug Resistance?
  10. Placenta analysis of Hofbauer cell profile according to the class of antiretroviral therapy used during pregnancy in people living with HIV.